PHARMACOECONOMIC EVLUATION OF 5-ASA APPLICATION IN LIGHT AND MEDIUM GRAVE DISSEMINATED (RECURRING) ULCERATIVE COLITIS

PHARMACOECONOMIC EVLUATION OF 5-ASA APPLICATION IN LIGHT AND MEDIUM GRAVE DISSEMINATED (RECURRING) ULCERATIVE COLITIS

Inflammatory bowel diseases are chronic relapsing immune-mediated diseases affecting the gastrointestinal tract. The goal of therapy of ulcerative colitis (one of the IBD variants) is the achievement and maintenance of steroid-free remission, prevention of UC complications, prevention of surgeries a...

Full description

Bibliographic Details
Main Author:	P. A. Balunov
Format:	Article
Language:	Russian
Published:	Remedium Group LLC 2017-11-01
Series:	Медицинский совет
Subjects:	ulcerative colitis uc 5-asa mesalazine mesacol sulfasalazine infliximab relapse remission
Online Access:	https://www.med-sovet.pro/jour/article/view/2076

Similar Items

Incidence of Ulcerative Colitis Relapse: A Prospective Cohort Study in Southern Iran
by: Seyed Vahid Hosseini, et al.
Published: (2016-03-01)

Management and treatment of distal ulcerative colitis
by: Andrea Calafiore, et al.
Published: (2013-12-01)

Drug-induced nephrolithiasis and crystalluria: the particular case of the sulfasalazine derivatives
by: Chebion, Guillaume, et al.
Published: (2021-09-01)

MESALAZINE PLACE IN THERAPY OF ULCERATIVE COLITIS
by: I. G. Bakulin, et al.
Published: (2017-11-01)

Prospects of MMX Mesalazine in Routine Outpatient Treatment of Ulcerative Colitis
by: Yu. P. Uspenskiy, et al.
Published: (2022-03-01)

DECISION TREE CONSTRUCTION AND COST-EFFECTIVENESS ANALYSIS OF TREATMENT OF ULCERATIVE COLITIS WITH PENTASA®MESALAZINE 2 G SACHET
by: Alvaro Mitsunori NISHIKAWA, et al.

Evaluation of the efficacy of MMX mesalazine therapy for moderate ulcerative colitis
by: O. V. Knyazev, et al.
Published: (2021-05-01)

Acute Pancreatitis due to pH-Dependent Mesalazine That Occurred in the Course of Ulcerative Colitis
by: Yoshinori Arai, et al.
Published: (2011-10-01)

Causes, frequencies, and predictors of relapse in patients with ulcerative colitis on long-term follow-up in a tertiary care hospital of Northern India
by: Rahul Jain, et al.
Published: (2022-01-01)

The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
by: Ohtaki Yuichiro, et al.
Published: (2022-08-01)

Evaluation of Proactive Therapeutic Drug Monitoring Application in Infliximab Users in Ulcerative Colitis
by: Gabriela Maria Henz Giovelli, et al.
Published: (2023-12-01)

Modern principles of conservative treatment of mild and moderate forms of ulcerative colitis
by: O. V. Golovenko
Published: (2022-11-01)

Comparative evaluation of the effectiveness of monotherapy of ulcerative colitis with mesalazine MMX and combination therapy with non-prolonged mesalazines with rectal forms
by: O. V. Knyazev, et al.
Published: (2022-08-01)

A Diagnostic Conundrum in a Newly Diagnosed Ulcerative Colitis Patient Who Presented with Pleuropericardial Effusion
by: Alpaslan Tanoglu, et al.
Published: (2019-06-01)

Comparing the Effects of Sulfasalazine and Shilajit on Liver Damage Caused by Acetic Acid-Induced Ulcerative Colitis in Male Rats
by: N Shahrokhi, et al.
Published: (2023-03-01)

Biological and histological parameters as predictors of relapse in ulcerative colitis: A prospective study
by: Sheenam Azad, et al.
Published: (2011-01-01)

Simultaneous Onset of Ulcerative Colitis and Disseminated Pyoderma Gangrenosum
by: Albrecht Neesse, et al.
Published: (2007-10-01)

THE RESULTS OF THE USE OF 5-AMINOSALICYLIC ACID AS AN ANTI-RELAPSE AND MAINTENANCE THERAPY ULCERATIVE COLITIS MODERATE SEVERITY IN CLINICAL PRACTICE
by: O. V. Knyazev, et al.
Published: (2018-01-01)

Integrated Analysis Reveals the Targets and Mechanisms in Immunosuppressive Effect of Mesalazine on Ulcerative Colitis
by: Rong Li, et al.
Published: (2022-05-01)

Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB)
by: Ligia Yukie Sassaki, et al.
Published: (2022-05-01)

Effect of montelukast on remission maintenance in patients with ulcerative colitis: a Randomized, double-blind controlled clinical trial
by: Kourosh Masnadi Shirazi, et al.
Published: (2025-03-01)

Acute transverse myelitis in an adult-patient with underlying ulcerative colitis: a case report
by: Yi Yang, et al.
Published: (2022-04-01)

A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis
by: Gionata Fiorino, et al.
Published: (2019-05-01)

A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis
by: Yamagami Hirokazu, et al.
Published: (2017-09-01)

Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
by: Haruhiko Ogata, et al.
Published: (2017-07-01)

Drugs for the treatment of ulcerative colitis on the pharmaceutical market of Ukraine
by: L. M. Palchak, et al.
Published: (2023-02-01)

SOME ASPECTS OF TREATMENT FOR LEFT-SIDED ULCERATIVE COLITIS
by: P. A. Makarchuk, et al.
Published: (2016-02-01)

Effect of shilajit on the levels of pro-inflammatory and anti inflammatory cytokines in ulcerative colitis induced by acetic acid in male rats
by: Fatemeh Alimahdi, et al.
Published: (2020-09-01)

Comparison of efficacy of once daily multimatrix mesalazine 2.4 g/day and 4.8 g/day with other 5-aminosalicylic acid preparation in active ulcerative colitis: a randomized, double-blind study
by: Haruhiko Ogata, et al.
Published: (2018-04-01)

A case of ulcerative colitis complicated by a simple appendiceal opening
by: Xiao Liu, et al.
Published: (2024-04-01)

Effectiveness of treatment of moderate ulcerative colitis with prolonged mesalazine in real clinical practice
by: O. V. Knyazev, et al.
Published: (2021-10-01)

Effects of Platelet-Rich Plasma on Clinical and Inflammatory Manifestations in an Experimental Model of Ulcerative Colitis
by: Maryam Ranjbar Bushehri, et al.
Published: (2023-12-01)

Long-term infliximab therapy for ulcerative colitis in real clinical practice
by: O V Knyazev, et al.
Published: (2016-08-01)

Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab Pioderma gangrenoso asociado a colitis ulcerosa: respuesta a infliximab
by: A. López San Román, et al.
Published: (2004-06-01)

Green tea polyphenols and sulfasalazine have parallel anti-inflammatory properties in colitis models
by: Helieh S Oz, et al.
Published: (2013-06-01)

Ulcerative colitis – recent and potential methods of treatment - review
by: Mikołaj Tomasik, et al.
Published: (2023-01-01)

Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study
by: Masakazu Nagahori, et al.
Published: (2017-04-01)

Promising effect of infliximab on the extent of involvement in ulcerative colitis
by: Peyman Adibi, et al.
Published: (2011-01-01)

Predictors of infliximab efficacy in patients with severe attack of ulcerative colitis
by: A. O. Golovenko, et al.
Published: (2013-10-01)

The effectiveness of mesalazine therapy of ulcerative colitis of moderate severity in real clinical practice
by: O. V. Knyazev, et al.
Published: (2019-10-01)